Gustave Roussy Research 🔬
@gr-research.bsky.social
Pioneering oncology research. Bridging fundamental, translational, and clinical research to advance precision medicine. 👩🔬👨🔬
🔗 www.gustaveroussy.fr
🔗 www.gustaveroussy.fr
Reposted by Gustave Roussy Research 🔬
🔹 Tarek Ben Ahmed presenting in the Poster Session on Prevention, Risk Reduction, and Genetics: One-year impact of a large-scale pilot multimodal personalized early #cancer detection and prevention program for individuals at high risk of cancer.
@ascocancer.bsky.social #ASCO25 #ASCO
@ascocancer.bsky.social #ASCO25 #ASCO
June 1, 2025 at 4:58 PM
🔹 Tarek Ben Ahmed presenting in the Poster Session on Prevention, Risk Reduction, and Genetics: One-year impact of a large-scale pilot multimodal personalized early #cancer detection and prevention program for individuals at high risk of cancer.
@ascocancer.bsky.social #ASCO25 #ASCO
@ascocancer.bsky.social #ASCO25 #ASCO
Reposted by Gustave Roussy Research 🔬
🔹 Gustave Roussy at #ASCO25 🔹
Ines Vaz Luis at @ascocancer.bsky.social on eHealth in breast #cancer: bridging the gap in survivorship with decision-support tools, care coordination, self-management, and digital supportive care.
#BreastCancer #Survivorship #eHealth
Ines Vaz Luis at @ascocancer.bsky.social on eHealth in breast #cancer: bridging the gap in survivorship with decision-support tools, care coordination, self-management, and digital supportive care.
#BreastCancer #Survivorship #eHealth
May 31, 2025 at 1:34 PM
🔹 Gustave Roussy at #ASCO25 🔹
Ines Vaz Luis at @ascocancer.bsky.social on eHealth in breast #cancer: bridging the gap in survivorship with decision-support tools, care coordination, self-management, and digital supportive care.
#BreastCancer #Survivorship #eHealth
Ines Vaz Luis at @ascocancer.bsky.social on eHealth in breast #cancer: bridging the gap in survivorship with decision-support tools, care coordination, self-management, and digital supportive care.
#BreastCancer #Survivorship #eHealth
Reposted by Gustave Roussy Research 🔬
🔹 Gustave Roussy at #ASCO25 🔹
Dr. Pablo Berlanga, paediatric oncologist at @gustaveroussy.fr, presents an innovative combination being tested as a first-line treatment for late diagnosis of Ewing's sarcoma at @ascocancer.bsky.social.
Press release ⤵
#ASCO
Dr. Pablo Berlanga, paediatric oncologist at @gustaveroussy.fr, presents an innovative combination being tested as a first-line treatment for late diagnosis of Ewing's sarcoma at @ascocancer.bsky.social.
Press release ⤵
#ASCO
ASCO 2025 - A new drug tested as a first-line treatment for poor-prognosis Ewing sarcomas | Gustave Roussy
ASCO 2025 – Oral abstract session Villejuif, 31 May 2025A new drug tested as a first-line treatment for poor-prognosis Ewing sarcomasRegorafenib is a new drug that helps slow the progression of certai...
www.gustaveroussy.fr
June 1, 2025 at 7:48 AM
🔹 Gustave Roussy at #ASCO25 🔹
Dr. Pablo Berlanga, paediatric oncologist at @gustaveroussy.fr, presents an innovative combination being tested as a first-line treatment for late diagnosis of Ewing's sarcoma at @ascocancer.bsky.social.
Press release ⤵
#ASCO
Dr. Pablo Berlanga, paediatric oncologist at @gustaveroussy.fr, presents an innovative combination being tested as a first-line treatment for late diagnosis of Ewing's sarcoma at @ascocancer.bsky.social.
Press release ⤵
#ASCO
Reposted by Gustave Roussy Research 🔬
🔹 Gustave Roussy at #ASCO25 🔹
Dr Pablo Berlanga, onco-pédiatre à @gustaveroussy.fr, présente une combinaison innovante testée en première ligne dans les sarcomes d'Ewing diagnostiqués tardivement à l'#ASCO. ⤵
@ascocancer.bsky.social
Dr Pablo Berlanga, onco-pédiatre à @gustaveroussy.fr, présente une combinaison innovante testée en première ligne dans les sarcomes d'Ewing diagnostiqués tardivement à l'#ASCO. ⤵
@ascocancer.bsky.social
Dr Pablo Berlanga - ASCO 2025
YouTube video by Gustave Roussy
www.youtube.com
June 1, 2025 at 7:51 AM
🔹 Gustave Roussy at #ASCO25 🔹
Dr Pablo Berlanga, onco-pédiatre à @gustaveroussy.fr, présente une combinaison innovante testée en première ligne dans les sarcomes d'Ewing diagnostiqués tardivement à l'#ASCO. ⤵
@ascocancer.bsky.social
Dr Pablo Berlanga, onco-pédiatre à @gustaveroussy.fr, présente une combinaison innovante testée en première ligne dans les sarcomes d'Ewing diagnostiqués tardivement à l'#ASCO. ⤵
@ascocancer.bsky.social
Reposted by Gustave Roussy Research 🔬
🔹 Gustave Rouss at ASCO 2025 🔹
Prof. Laurence Zitvogel presents microbiome session at #ASCO.
@ascocancer.bsky.social
Prof. Laurence Zitvogel presents microbiome session at #ASCO.
@ascocancer.bsky.social
June 1, 2025 at 7:56 AM
🔹 Gustave Rouss at ASCO 2025 🔹
Prof. Laurence Zitvogel presents microbiome session at #ASCO.
@ascocancer.bsky.social
Prof. Laurence Zitvogel presents microbiome session at #ASCO.
@ascocancer.bsky.social
Reposted by Gustave Roussy Research 🔬
🔹 Gustave Roussy at #ASCO25 🔹
Barbara Pistilli discusses the positioning of Dato-DXd in the rapidly evolving landscape of ER-positive, HER2-low breast #cancer.
@ascocancer.bsky.social
Barbara Pistilli discusses the positioning of Dato-DXd in the rapidly evolving landscape of ER-positive, HER2-low breast #cancer.
@ascocancer.bsky.social
May 31, 2025 at 6:27 AM
🔹 Gustave Roussy at #ASCO25 🔹
Barbara Pistilli discusses the positioning of Dato-DXd in the rapidly evolving landscape of ER-positive, HER2-low breast #cancer.
@ascocancer.bsky.social
Barbara Pistilli discusses the positioning of Dato-DXd in the rapidly evolving landscape of ER-positive, HER2-low breast #cancer.
@ascocancer.bsky.social
Reposted by Gustave Roussy Research 🔬
🔹 Gustave Roussy à l'#ASCO25 🔹
Dr Antoine Hollebecque, oncologue à @gustaveroussy.fr, présente une nouvelle association de traitements pour les patients avec un cancer colorectal en échec thérapeutique à l'@ascocancer.bsky.social. ⤵
Dr Antoine Hollebecque, oncologue à @gustaveroussy.fr, présente une nouvelle association de traitements pour les patients avec un cancer colorectal en échec thérapeutique à l'@ascocancer.bsky.social. ⤵
Dr Antoine Hollebecque - ASCO 2025
YouTube video by Gustave Roussy
www.youtube.com
May 31, 2025 at 6:25 AM
🔹 Gustave Roussy à l'#ASCO25 🔹
Dr Antoine Hollebecque, oncologue à @gustaveroussy.fr, présente une nouvelle association de traitements pour les patients avec un cancer colorectal en échec thérapeutique à l'@ascocancer.bsky.social. ⤵
Dr Antoine Hollebecque, oncologue à @gustaveroussy.fr, présente une nouvelle association de traitements pour les patients avec un cancer colorectal en échec thérapeutique à l'@ascocancer.bsky.social. ⤵
Reposted by Gustave Roussy Research 🔬
🔹 Gustave Roussy at #ASCO25. 🔹
The Institute's experts have arrived on site. Follow them throughout the weekend.
@ascocancer.bsky.social
The Institute's experts have arrived on site. Follow them throughout the weekend.
@ascocancer.bsky.social
May 31, 2025 at 6:08 AM
🔹 Gustave Roussy at #ASCO25. 🔹
The Institute's experts have arrived on site. Follow them throughout the weekend.
@ascocancer.bsky.social
The Institute's experts have arrived on site. Follow them throughout the weekend.
@ascocancer.bsky.social
Reposted by Gustave Roussy Research 🔬
🚀 #ASCO25 is on!
Keep up to date with news from @gustaveroussy.fr's doctors and researchers on social networks throughout the weekend. @ascocancer.bsky.social
Keep up to date with news from @gustaveroussy.fr's doctors and researchers on social networks throughout the weekend. @ascocancer.bsky.social
May 30, 2025 at 1:46 PM
🚀 #ASCO25 is on!
Keep up to date with news from @gustaveroussy.fr's doctors and researchers on social networks throughout the weekend. @ascocancer.bsky.social
Keep up to date with news from @gustaveroussy.fr's doctors and researchers on social networks throughout the weekend. @ascocancer.bsky.social
New data in pancreatic #cancer!
The NEOPAN Phase III trial led by Prof. Michel Ducreux (@gustaveroussy.fr) shows FOLFIRINOX improves PFS vs gemcitabine in LAPC, with similar OS and QoL.
👉 doi.org/10.1200/JCO-...
#PancreaticCancer #OncoResearch #FOLFIRINOX
The NEOPAN Phase III trial led by Prof. Michel Ducreux (@gustaveroussy.fr) shows FOLFIRINOX improves PFS vs gemcitabine in LAPC, with similar OS and QoL.
👉 doi.org/10.1200/JCO-...
#PancreaticCancer #OncoResearch #FOLFIRINOX
May 28, 2025 at 7:06 AM
New data in pancreatic #cancer!
The NEOPAN Phase III trial led by Prof. Michel Ducreux (@gustaveroussy.fr) shows FOLFIRINOX improves PFS vs gemcitabine in LAPC, with similar OS and QoL.
👉 doi.org/10.1200/JCO-...
#PancreaticCancer #OncoResearch #FOLFIRINOX
The NEOPAN Phase III trial led by Prof. Michel Ducreux (@gustaveroussy.fr) shows FOLFIRINOX improves PFS vs gemcitabine in LAPC, with similar OS and QoL.
👉 doi.org/10.1200/JCO-...
#PancreaticCancer #OncoResearch #FOLFIRINOX
🚨Few days left!
Join us this Friday, May 16 at 13:30 (Paris time) for a deep dive into computational methods for spatial omics analyses.
🔍 Discover how Sopa and Novae, two open-source powerfool tools for spatial transcriptomics research.
⬇
Join us this Friday, May 16 at 13:30 (Paris time) for a deep dive into computational methods for spatial omics analyses.
🔍 Discover how Sopa and Novae, two open-source powerfool tools for spatial transcriptomics research.
⬇
May 13, 2025 at 12:56 PM
🚨Few days left!
Join us this Friday, May 16 at 13:30 (Paris time) for a deep dive into computational methods for spatial omics analyses.
🔍 Discover how Sopa and Novae, two open-source powerfool tools for spatial transcriptomics research.
⬇
Join us this Friday, May 16 at 13:30 (Paris time) for a deep dive into computational methods for spatial omics analyses.
🔍 Discover how Sopa and Novae, two open-source powerfool tools for spatial transcriptomics research.
⬇
Reposted by Gustave Roussy Research 🔬
Researchers from the Crick, @ucl.ac.uk, @gr-research.bsky.social and @mskcancercenter.bsky.social have discovered that certain age-related genetic changes in the blood are associated with worse outcomes for cancer patients.
www.crick.ac.uk/news/2025-04...
www.crick.ac.uk/news/2025-04...
Age-related genetic changes in the blood associated with poor cancer prognosis
Researchers from the Francis Crick Institute, UCL, Gustave Roussy and Memorial Sloan Kettering Cancer Center (MSK), have discovered that expansion of mutant blood cells, a phenomenon linked to ageing,...
www.crick.ac.uk
April 24, 2025 at 2:24 PM
Researchers from the Crick, @ucl.ac.uk, @gr-research.bsky.social and @mskcancercenter.bsky.social have discovered that certain age-related genetic changes in the blood are associated with worse outcomes for cancer patients.
www.crick.ac.uk/news/2025-04...
www.crick.ac.uk/news/2025-04...
📢 Excited to launch Signadori Bio with Sofinnova Partners!
Born from @gustaveroussy.fr research, this new biotech develops breakthrough cell therapies for #cancer. ⤵
#CellTherapy #CancerResearch #Biotech #OncologyInnovation #TranslationalResearch #GustaveRoussy #SofinnovaPartners #SignadoriBio
Born from @gustaveroussy.fr research, this new biotech develops breakthrough cell therapies for #cancer. ⤵
#CellTherapy #CancerResearch #Biotech #OncologyInnovation #TranslationalResearch #GustaveRoussy #SofinnovaPartners #SignadoriBio
Sofinnova Partners and Gustave Roussy launch first biotech company through Strategic Partnership — Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of prof...
sofinnovapartners.com
April 7, 2025 at 8:38 AM
📢 Excited to launch Signadori Bio with Sofinnova Partners!
Born from @gustaveroussy.fr research, this new biotech develops breakthrough cell therapies for #cancer. ⤵
#CellTherapy #CancerResearch #Biotech #OncologyInnovation #TranslationalResearch #GustaveRoussy #SofinnovaPartners #SignadoriBio
Born from @gustaveroussy.fr research, this new biotech develops breakthrough cell therapies for #cancer. ⤵
#CellTherapy #CancerResearch #Biotech #OncologyInnovation #TranslationalResearch #GustaveRoussy #SofinnovaPartners #SignadoriBio
📰 New ERN-EuroBloodNet guidelines for adult Burkitt lymphoma now published in The Lancet Haematology. First EU-wide recommendations to harmonise diagnosis, risk-adapted treatment & prognosis.
🔗 doi.org/10.1016/S235...
#Lymphoma #Haematology
🔗 doi.org/10.1016/S235...
#Lymphoma #Haematology
April 3, 2025 at 1:21 PM
📰 New ERN-EuroBloodNet guidelines for adult Burkitt lymphoma now published in The Lancet Haematology. First EU-wide recommendations to harmonise diagnosis, risk-adapted treatment & prognosis.
🔗 doi.org/10.1016/S235...
#Lymphoma #Haematology
🔗 doi.org/10.1016/S235...
#Lymphoma #Haematology
📢 New publication from @gustaveroussy.fr researchers & collaborators in Nature Cancer further supports the tumor-agnostic indication of pembrolizumab ! 📢
Read the study: doi.org/10.1038/s430...
Read the study: doi.org/10.1038/s430...
March 26, 2025 at 3:13 PM
📢 New publication from @gustaveroussy.fr researchers & collaborators in Nature Cancer further supports the tumor-agnostic indication of pembrolizumab ! 📢
Read the study: doi.org/10.1038/s430...
Read the study: doi.org/10.1038/s430...
Reposted by Gustave Roussy Research 🔬
Congrats to Thomas Mercher @gustaveroussy.fr, Erika Brunet @institutimagine.bsky.social and all involved in this beautiful study just out in Blood ⤵️
NEW PUBLICATION!
Researchers from the @r4knetwork.bsky.social just revealed the progressive chromatin rewiring induced by the ETO2::GLIS2 fusion in the onset of pediatric leukemia.
A collaboration between @gustaveroussy.fr, @institutimagine.bsky.social, & many more.
doi.org/10.1182/bloo...
Researchers from the @r4knetwork.bsky.social just revealed the progressive chromatin rewiring induced by the ETO2::GLIS2 fusion in the onset of pediatric leukemia.
A collaboration between @gustaveroussy.fr, @institutimagine.bsky.social, & many more.
doi.org/10.1182/bloo...
Progressive chromatin rewiring by ETO2::GLIS2 revealed in a human iPSC model of pediatric leukemia initiation
Key Points. Precise engineering of the ETO2::GLIS2 fusion in iPSC reproduces leukemogenesis in a developmentally-relevant human cell contextThe temporal or
ashpublications.org
March 24, 2025 at 2:54 PM
Congrats to Thomas Mercher @gustaveroussy.fr, Erika Brunet @institutimagine.bsky.social and all involved in this beautiful study just out in Blood ⤵️
Reposted by Gustave Roussy Research 🔬
NEW PUBLICATION!
Researchers from the @r4knetwork.bsky.social just revealed the progressive chromatin rewiring induced by the ETO2::GLIS2 fusion in the onset of pediatric leukemia.
A collaboration between @gustaveroussy.fr, @institutimagine.bsky.social, & many more.
doi.org/10.1182/bloo...
Researchers from the @r4knetwork.bsky.social just revealed the progressive chromatin rewiring induced by the ETO2::GLIS2 fusion in the onset of pediatric leukemia.
A collaboration between @gustaveroussy.fr, @institutimagine.bsky.social, & many more.
doi.org/10.1182/bloo...
Progressive chromatin rewiring by ETO2::GLIS2 revealed in a human iPSC model of pediatric leukemia initiation
Key Points. Precise engineering of the ETO2::GLIS2 fusion in iPSC reproduces leukemogenesis in a developmentally-relevant human cell contextThe temporal or
ashpublications.org
March 24, 2025 at 2:52 PM
NEW PUBLICATION!
Researchers from the @r4knetwork.bsky.social just revealed the progressive chromatin rewiring induced by the ETO2::GLIS2 fusion in the onset of pediatric leukemia.
A collaboration between @gustaveroussy.fr, @institutimagine.bsky.social, & many more.
doi.org/10.1182/bloo...
Researchers from the @r4knetwork.bsky.social just revealed the progressive chromatin rewiring induced by the ETO2::GLIS2 fusion in the onset of pediatric leukemia.
A collaboration between @gustaveroussy.fr, @institutimagine.bsky.social, & many more.
doi.org/10.1182/bloo...
📣 We are excited to announce the first scientific day on liquid biopsy, organized by @gustaveroussy.fr and the IHU PRISM, taking place on June 11, 2025, in Paris! 🧬🔬
🔗 More information & registration:
🔗 More information & registration:
École des sciences du cancer
gustaveroussy.my.site.com
March 21, 2025 at 9:59 AM
📣 We are excited to announce the first scientific day on liquid biopsy, organized by @gustaveroussy.fr and the IHU PRISM, taking place on June 11, 2025, in Paris! 🧬🔬
🔗 More information & registration:
🔗 More information & registration:
📰 Low-dose gut radiation enhances immunotherapy.
New #research shows it boosts PD-L1 blockade, triggering a stronger systemic anti-tumor immune response. The gut microbiome plays a key role—this could be a game-changer for #cancer treatment.
#Immunotherapy #Oncology #PDL1
New #research shows it boosts PD-L1 blockade, triggering a stronger systemic anti-tumor immune response. The gut microbiome plays a key role—this could be a game-changer for #cancer treatment.
#Immunotherapy #Oncology #PDL1
March 19, 2025 at 2:43 PM
📰 Low-dose gut radiation enhances immunotherapy.
New #research shows it boosts PD-L1 blockade, triggering a stronger systemic anti-tumor immune response. The gut microbiome plays a key role—this could be a game-changer for #cancer treatment.
#Immunotherapy #Oncology #PDL1
New #research shows it boosts PD-L1 blockade, triggering a stronger systemic anti-tumor immune response. The gut microbiome plays a key role—this could be a game-changer for #cancer treatment.
#Immunotherapy #Oncology #PDL1
Reposted by Gustave Roussy Research 🔬
📰 Des chercheurs parviennent à reproduire une leucémie pédiatrique à partir de cellules humaines non-cancéreuses.
Communiqué de presse ⤵
Communiqué de presse ⤵
BLOOD - Des chercheurs parviennent à reproduire une leucémie pédiatrique à partir de cellules humaines non-cancéreuses | Gustave Roussy
Villejuif, le 13 mars 2025BLOOD - Des chercheurs parviennent à reproduire une leucémie pédiatrique à partir de cellules humaines non-cancéreusesL’équipe Inserm dirigée par Thomas Mercher à Gustave Rou...
www.gustaveroussy.fr
March 13, 2025 at 2:33 PM
📰 Des chercheurs parviennent à reproduire une leucémie pédiatrique à partir de cellules humaines non-cancéreuses.
Communiqué de presse ⤵
Communiqué de presse ⤵
📰 “De-escalation in Lung Cancer Treatment: Are We Ready?”
A new review in JCO explores de-escalation strategies for ICBs in NSCLC—reducing dose, duration, or frequency—to cut toxicity, costs, and improve global access without compromising efficacy.
🔗 ascopubs.org/doi/full/10....
A new review in JCO explores de-escalation strategies for ICBs in NSCLC—reducing dose, duration, or frequency—to cut toxicity, costs, and improve global access without compromising efficacy.
🔗 ascopubs.org/doi/full/10....
March 13, 2025 at 10:46 AM
📰 “De-escalation in Lung Cancer Treatment: Are We Ready?”
A new review in JCO explores de-escalation strategies for ICBs in NSCLC—reducing dose, duration, or frequency—to cut toxicity, costs, and improve global access without compromising efficacy.
🔗 ascopubs.org/doi/full/10....
A new review in JCO explores de-escalation strategies for ICBs in NSCLC—reducing dose, duration, or frequency—to cut toxicity, costs, and improve global access without compromising efficacy.
🔗 ascopubs.org/doi/full/10....
📰 Gustave Roussy Authorised to Conduct Phase I Clinical Trials in Nuclear Medicine.
🎯 The Institute can now evaluate innovative radioligands administered for the first time or at an early stage in humans.
More informations 👇
🎯 The Institute can now evaluate innovative radioligands administered for the first time or at an early stage in humans.
More informations 👇
Gustave Roussy Authorised to Conduct Phase I Clinical Trials in Nuclear Medicine
In 2024, the Nuclear Safety and Radiation Protection Authority (ASNR) and the Regional Health Agency (ARS) Île-de-France authorised Gustave Roussy to conduct Phase I trials in nuclear medicine, the fi...
www.gustaveroussy.fr
March 12, 2025 at 9:22 AM
📰 Gustave Roussy Authorised to Conduct Phase I Clinical Trials in Nuclear Medicine.
🎯 The Institute can now evaluate innovative radioligands administered for the first time or at an early stage in humans.
More informations 👇
🎯 The Institute can now evaluate innovative radioligands administered for the first time or at an early stage in humans.
More informations 👇
Congrès IFODS 2025 🚀
📅 Le 12/06/2025, lors du Congrès National d’Oncologie - IFODS, nous vous donnons rendez-vous pour une session Présidentielle : IFODS - Gustave Roussy », qui se déroulera sous la présidence de Fabrice Barlesi, Francoise Mornex et Jean-Philippe SPANO. ⤵
📅 Le 12/06/2025, lors du Congrès National d’Oncologie - IFODS, nous vous donnons rendez-vous pour une session Présidentielle : IFODS - Gustave Roussy », qui se déroulera sous la présidence de Fabrice Barlesi, Francoise Mornex et Jean-Philippe SPANO. ⤵
March 11, 2025 at 8:51 AM
Congrès IFODS 2025 🚀
📅 Le 12/06/2025, lors du Congrès National d’Oncologie - IFODS, nous vous donnons rendez-vous pour une session Présidentielle : IFODS - Gustave Roussy », qui se déroulera sous la présidence de Fabrice Barlesi, Francoise Mornex et Jean-Philippe SPANO. ⤵
📅 Le 12/06/2025, lors du Congrès National d’Oncologie - IFODS, nous vous donnons rendez-vous pour une session Présidentielle : IFODS - Gustave Roussy », qui se déroulera sous la présidence de Fabrice Barlesi, Francoise Mornex et Jean-Philippe SPANO. ⤵
Reposted by Gustave Roussy Research 🔬
📰 Le Dr Elie Rassy, oncologue médical au sein du comité de pathologie mammaire de Gustave Roussy et co-investigateur d’ETNA, revient en cinq questions sur cet essai clinique.
⤵⤵⤵
⤵⤵⤵
5 questions au Dr Elie Rassy sur l’essai clinique ETNA dans les cancers du sein triple négatif
Ouvert en décembre 2024, ETNA est un essai clinique pragmatique qui s’adresse aux femmes atteintes d’un cancer du sein triple négatif de stade précoce. Il s’inscrit dans une démarche de désescalade th...
www.gustaveroussy.fr
March 10, 2025 at 10:07 AM
📰 Le Dr Elie Rassy, oncologue médical au sein du comité de pathologie mammaire de Gustave Roussy et co-investigateur d’ETNA, revient en cinq questions sur cet essai clinique.
⤵⤵⤵
⤵⤵⤵
🚀 Join us at the inaugural AI in Oncology 2025 Conference ! 🚀
📅 June 17-18, 2025
📍 Paris, France
🌍 Bringing together top researchers, clinicians, and industry leaders
🔗 Register now and be part of the conversation: www.aiinoncology.com
📅 June 17-18, 2025
📍 Paris, France
🌍 Bringing together top researchers, clinicians, and industry leaders
🔗 Register now and be part of the conversation: www.aiinoncology.com
March 5, 2025 at 2:21 PM
🚀 Join us at the inaugural AI in Oncology 2025 Conference ! 🚀
📅 June 17-18, 2025
📍 Paris, France
🌍 Bringing together top researchers, clinicians, and industry leaders
🔗 Register now and be part of the conversation: www.aiinoncology.com
📅 June 17-18, 2025
📍 Paris, France
🌍 Bringing together top researchers, clinicians, and industry leaders
🔗 Register now and be part of the conversation: www.aiinoncology.com